Redhill Biopharma Ltd (NAS:RDHL)
RedHill Biopharma Ltd. is a NASDAQ listed drug manufacturer based in Israel. The company is focused on late clinical-stage, orally-administered drugs for the treatment of internal inflammatory disorders such as gastroenteritis.
|10 Days Avg Vol||34,157.93|
|3 Mo Avg Vol||136,806.71|
|52 Wk Lo/Hi||$4.300 - $11.250|
|YTD Price Gain %||-100%|
|12 Wks Moving Avg||5.839989|
|200 Days Moving Avg||7.610404|
Updated: Market Close, 02/22/2018
RedHill Biopharma Ltd. is an Israel-based developer of pharmaceutical products addressing multiple diseases. Its primary focus lies on late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of internal inflammatory disorders and cancer. Redhill's assortment of drugs includes RHB-105, which combats the Helicobacter pylori infection; RHB-104, which treats the Crohn's disease and RIZAPORT, for acute migraines. The BEKINDA, YELIVA and MESUPRON were formulated for acute gastroenteritis and other critical inflammatory conditions.
No management profiles found.